CPRX (Catalyst Pharmaceuticals) ROE % Adjusted to Book Value : 9.29% (As of Dec. 2024)

View and export this data going back to 2006. Start your Free Trial

What is Catalyst Pharmaceuticals ROE % Adjusted to Book Value?

Catalyst Pharmaceuticals's ROE % for the quarter that ended in Dec. 2024 was 32.23%. Catalyst Pharmaceuticals's PB Ratio for the quarter that ended in Dec. 2024 was 3.47. Catalyst Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 was 9.29%.

Catalyst Pharmaceuticals ROE % Adjusted to Book Value Historical Data

The historical data trend for Catalyst Pharmaceuticals's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Catalyst Pharmaceuticals ROE % Adjusted to Book Value Chart

Catalyst Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

28.58

6.23

5.02

4.47

8.47

Catalyst Pharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															8.16	5.85	9.24	7.70	9.29

Competitive Comparison of Catalyst Pharmaceuticals's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Catalyst Pharmaceuticals's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Catalyst Pharmaceuticals's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Catalyst Pharmaceuticals's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Catalyst Pharmaceuticals's ROE % Adjusted to Book Value falls into.

Catalyst Pharmaceuticals ROE % Adjusted to Book Value Calculation

Catalyst Pharmaceuticals's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	29.38%	/	3.47
	=	8.47%

Catalyst Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	32.23%	/	3.47
	=	9.29%

Catalyst Pharmaceuticals ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Catalyst Pharmaceuticals's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Catalyst Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Catalyst Pharmaceuticals Inc (NAS:CPRX) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

CN2:Germany CN2:Germany

Address

355 Alhambra Circle, Suite 801, Coral Gables, FL, USA, 33134

Website

https://www.catalystpharma.com

Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).

Executives

Gary Ingenito	officer: Chief Medical Officer	355 ALHAMBRA CIRCLE, SUITE 1500, CORAL GABLES FL 33134
Carmen Jeffrey Del	officer: Chief Commercial Officer	355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES FL 33134
Brian Elsbernd	officer: Chief Compliance/Legal Officer	355 ALHAMBRA CIRCLE, CORAL GABLES FL 33134
Steve Miller	officer: VP Development & Management	220 MIRACLE MILE, SUITE 234, CORAL GABLES FL 33134
Molly Harper	director	355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES FL 33134
Patrick J Mcenany	director, 10 percent owner, officer: President and Chief Executive	C/O THERMOGENESIS CORP, 2711 CITRUS ROAD, RANCHO CORDOVA CA 95742
David S Tierney	director	C/O ABLE LABORATORIES, INC., 6 HOLLYWOOD COURT, CN 1013, SOUTH PLAINFIELD NJ 07080
Richard J Daly	director	355 ALHAMBRA CIRCLE, SUITE 1500, CORAL GABLES FL 33134
Alicia Grande	officer: Chief Accounting Officer	220 MIRACLE MILE, SUITE 234, CORAL GABLES FL 33134
Tamar Thompson	director	C/O AVIDITY BIOSCIENCES, INC., 10975 N. TORREY PINES RD., SUITE 150, LA JOLLA CA 92037
Philip H Coelho	director	C/O THERMOGENESIS CORP, 2711 CITRUS ROAD, RANCHO CORDOVA CA 95742
Charles B O'keeffe	director	220 MIRACLE MILE, SUITE 234, CORAL GABLES FL 33134
Preethi Sundaram	officer: Chief Product Devel. Officer	355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES FL 33134
Donald A Denkhaus	director	355 ALHAMBRA CIRCLE, SUITE 1500, CORAL GABLES FL 33134
Daniel Brennan	officer: Chief Commercial Officer	C/O INSYS THERAPEUTICS, INC, 1333 SOUTH SPECTRUM BLVD, SUITE 100, CHANDLER AZ 85286